Tiziana Life Sciences not to engage in capital raising activities for the immediate future

Core Insights - Tiziana Life Sciences has announced its intention not to engage in capital raising activities for the immediate future, following the discovery of new immune biomarkers in patients with non-active secondary progressive multiple sclerosis treated with nasal foralumab [1][2] Company Overview - Tiziana Life Sciences is a clinical-stage biopharmaceutical company focused on developing breakthrough therapies using innovative drug delivery technologies, particularly through nasal administration [3] - The lead candidate, intranasal foralumab, is a fully human anti-CD3 monoclonal antibody currently in clinical development, showing a favorable safety profile and clinical response in previous studies [3] - The company's nasal approach aims to improve efficacy, safety, and tolerability compared to traditional intravenous delivery methods [3] Commitment to Shareholders - The management team of Tiziana Life Sciences remains dedicated to delivering value to shareholders while advancing its innovative drug candidates through clinical trials and regulatory processes [2]